Ublituximab, Potential Relapsing MS Therapy, Up for FDA Approval
TG TherapeuticsĀ has applied to the U.S. Food and Drug Administration (FDA) for approval ofĀ ublituximab, the companyās investigational anti-CD20 monoclonal antibody therapy for relapsing forms of multiple sclerosis (RMS). Its application was based on data from the ULTIMATE 1 (NCT03277261) and ULTIMATE 2 (NCT03277248) Phase…